Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease (VINCA-CKD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01012414
Recruitment Status : Terminated (Futility in enrollment as of May 31, 2011)
First Posted : November 13, 2009
Results First Posted : November 11, 2013
Last Update Posted : May 20, 2014
Information provided by (Responsible Party):
Thomas Jefferson University

Brief Summary:
The purpose of this study is to determine if vitamin D supplementation changes the results of certain tests associated with inflammation in the body using an oral, synthetic form of vitamin D called paricalcitol.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Chronic Kidney Disease Hypovitaminosis D Secondary Hyperparathyroidism Drug: paricalcitol Drug: placebo Phase 3

Detailed Description:
Vitamin D deficiency is common and has been associated with an increased risk of heart disease. In patients with the combination of kidney disease and heart disease, inflammation is thought to contribute to a high rate of cardiac events. Less is known about the effects of vitamin D supplementation on certain tests associated with inflammation in the body.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D
Study Start Date : January 2010
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Arm Intervention/treatment
Experimental: oral paricalcitol 2 mcg daily
oral paricalcitol 2 mcg daily
Drug: paricalcitol
2 mcg oral paricalcitol daily
Other Name: Zemplar

Placebo Comparator: Placebo
one oral placebo drug daily
Drug: placebo

Primary Outcome Measures :
  1. Change in High Sensitivity-C Reactive Protein (Serum) [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A [ Time Frame: 1 year ]
  2. Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure. [ Time Frame: 1 year ]
  3. Effect on Carotid Intima-media Thickening (CIMT) [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and non-pregnant, non-lactating women greater than 18 years of age
  • Able to given informed consent and complete scheduled visits
  • History of established coronary artery disease (CAD)as defined by coronary stenosis in one or more vessels greater than or equal to 70% by coronary angiography or CT angiogram OR abnormal stress test (at least medium-sized, moderate reversible defect) OR a presence of a CAD risk equivalent as defined by the National Cholesterol Education Panel (NCEP)III as: Framingham risk score ≥ 20%, diabetes, or peripheral arterial disease(4)
  • High Sensitivity C-reactive Protein (hs-CRP) ≥ 2.0 mg/L
  • History of stage 3 or 4 chronic Kidney disease (CKD) defined as an glomerular filtration rate (eGRF) by the Modification of Diet in Renal Disease (MDRD) formula of 15-60 mL/min/1.73 m2
  • Low level of serum 25-hydroxyvitamin D (<30ng/mL)
  • Evidence of secondary hyperparathyroidism defined as intact parathyroid hormone (iPTH) level > 70 pg/mL
  • Stable dose of statin and/or other lipid lowering therapy (ie: ezetimibe, fibrates, bile acid sequestrants nicotinic acid, fish oil) for 12 weeks prior to enrollment without known plans for change to current therapy during the study period

Exclusion Criteria:

  • History of myocardial infarction, stroke, or cardiac surgery within 6 months of enrollment
  • History of carotid artery surgery
  • Planned cardiovascular surgery or procedure, with the exception of permanent pacemaker placement, in the next 18 months.
  • Use of vitamin D or calcium supplementation within the past 12 weeks with the exception of calcium containing phosphate binders and a daily multivitamin containing ≤ 400 IU of vitamin D
  • Hypercalcemia (as defined by the laboratory upper limit of normal ) or hyperphosphatemia (≥ 5.5 mg/dL)
  • Plan to initiate renal replacement therapy (dialysis) during the study
  • History of left ventricular systolic dysfunction with an ejection fraction <50% or history of New York Heart Association (NYHA)functional Class II-IV congestive heart failure
  • Uncontrolled blood pressure, defined as systolic blood pressure greater than 160 mmHg and diastolic blood pressure greater than 100 mm Hg at the screening visit
  • Uncontrolled diabetes, defined as hemoglobin A1C ≥ 10.0
  • History of any surgery within the past 3 months or known to be planned during the study period
  • History of malignancy within the past 5 years with the exception of non-melanoma (ie: squamous cell or basal cell) skin cancer
  • History of a known systemic or pulmonary inflammatory condition (including rheumatoid arthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease, pulmonary fibrosis, sarcoidosis, Wegener's granulomatosis, Goodpasture's disease)
  • History of renal or other organ transplant and/or immunosuppressed state (ie immunosuppressive therapy or condition such as HIV)
  • History of any other condition, that in the opinion of the investigators renders it unsafe for the subject to be enrolled
  • For woman able to become pregnant, unwillingness to use birth control
  • Participation in another clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01012414

United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University
Principal Investigator: David J Whellan, MD MHS Thomas Jefferson University

Responsible Party: Thomas Jefferson University Identifier: NCT01012414     History of Changes
Other Study ID Numbers: 09C.110
First Posted: November 13, 2009    Key Record Dates
Results First Posted: November 11, 2013
Last Update Posted: May 20, 2014
Last Verified: May 2014

Keywords provided by Thomas Jefferson University:
Vitamin D
Coronary Artery Disease (CAD)
Chronic Kidney Disease (CKD)

Additional relevant MeSH terms:
Kidney Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Renal Insufficiency, Chronic
Hyperparathyroidism, Secondary
Vitamin D Deficiency
Pathologic Processes
Urologic Diseases
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Renal Insufficiency
Parathyroid Diseases
Endocrine System Diseases
Deficiency Diseases
Nutrition Disorders
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Calcium Metabolism Disorders